BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haji Abdolvahab M, Moradi-Kalbolandi S, Zarei M, Bose D, Majidzadeh-A K, Farahmand L. Potential role of interferons in treating COVID-19 patients. Int Immunopharmacol 2021;90:107171. [PMID: 33221168 DOI: 10.1016/j.intimp.2020.107171] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Prasad AS, Malysa A, Bepler G, Fribley A, Bao B. The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19. Antioxidants 2022;11:1862. [DOI: 10.3390/antiox11101862] [Reference Citation Analysis]
2 Wang J, Li Q, Qiu Y, Lu H. COVID-19: imbalanced cell-mediated immune response drives to immunopathology. Emerg Microbes Infect 2022;:1-28. [PMID: 36069182 DOI: 10.1080/22221751.2022.2122579] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Karyana M, Djaharuddin I, Rif'ati L, Arif M, Choi MK, Angginy N, Yoon A, Han J, Josh F, Arlinda D, Narulita A, Muchtar F, Bakri RA, Irmansyah S. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther 2022;13:134. [PMID: 35365239 DOI: 10.1186/s13287-022-02812-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Shirvani F, Babaie D, Karimi AM. COVID-19 and Influenza: Differences, Similarities, and Coinfection. Arch Pediatr Infect Dis 2022;In Press. [DOI: 10.5812/pedinfect.114358] [Reference Citation Analysis]
5 Rusu I, Turlacu M, Micheu MM. Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications. World J Clin Cases 2022; 10(3): 762-776 [DOI: 10.12998/wjcc.v10.i3.762] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Fouladseresht H, Ghamar Talepoor A, Eskandari N, Norouzian M, Ghezelbash B, Beyranvand MR, Nejadghaderi SA, Carson-chahhoud K, Kolahi A, Safiri S. Potential Immune Indicators for Predicting the Prognosis of COVID-19 and Trauma: Similarities and Disparities. Front Immunol 2022;12:785946. [DOI: 10.3389/fimmu.2021.785946] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lazo L, Bequet-romero M, Lemos G, Musacchio A, Cabrales A, Bruno AJ, Ariel Espinosa L, Saloheimo M, Vitikainen M, Hernández A, Emalfarb M, Tchelet R, Suzarte E, Guillén G. A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cojocaru E, Cojocaru C, Antoniu SA, Stafie CS, Rajnoveanu A, Rajnoveanu RM. Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective. Expert Rev Respir Med 2021;:1-5. [PMID: 34793285 DOI: 10.1080/17476348.2022.2008910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Nabi-Afjadi M, Karami H, Goudarzi K, Alipourfard I, Bahreini E. The effect of vitamin D, magnesium and zinc supplements on interferon signaling pathways and their relationship to control SARS-CoV-2 infection. Clin Mol Allergy 2021;19:21. [PMID: 34749737 DOI: 10.1186/s12948-021-00161-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Butt RT, Janjua OS, Qureshi SM, Shaikh MS, Guerrero-Gironés J, Rodríguez-Lozano FJ, Zafar MS. Dental Healthcare Amid the COVID-19 Pandemic. Int J Environ Res Public Health 2021;18:11008. [PMID: 34769526 DOI: 10.3390/ijerph182111008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dominguez-Nicolas SM, Manjarrez E. Low-field thoracic magnetic stimulation increases peripheral oxygen saturation levels in coronavirus disease (COVID-19) patients: A single-blind, sham-controlled, crossover study. Medicine (Baltimore) 2021;100:e27444. [PMID: 34622862 DOI: 10.1097/MD.0000000000027444] [Reference Citation Analysis]
12 Soh SM, Kim Y, Kim C, Jang US, Lee HR. The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance. J Microbiol 2021;59:807-18. [PMID: 34449057 DOI: 10.1007/s12275-021-1348-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Moubarak M, Kasozi KI, Hetta HF, Shaheen HM, Rauf A, Al-Kuraishy HM, Qusti S, Alshammari EM, Ayikobua ET, Ssempijja F, Afodun AM, Kenganzi R, Usman IM, Ochieng JJ, Osuwat LO, Matama K, Al-Gareeb AI, Kairania E, Musenero M, Welburn SC, Batiha GE. The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections. Life (Basel) 2021;11:734. [PMID: 34440478 DOI: 10.3390/life11080734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
14 Park A, Harris LK. Gene Expression Meta-Analysis Reveals Interferon-Induced Genes Associated With SARS Infection in Lungs. Front Immunol 2021;12:694355. [PMID: 34367154 DOI: 10.3389/fimmu.2021.694355] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Vanden Eynde JJ. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes? Pharmaceuticals (Basel) 2021;14:664. [PMID: 34358090 DOI: 10.3390/ph14070664] [Reference Citation Analysis]
16 Monschein T, Zrzavy T, Löbermann M, Winkelmann A, Berger T, Rommer P, Hartung HP, Zettl UK. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations]. Nervenarzt 2021. [PMID: 34232359 DOI: 10.1007/s00115-021-01155-4] [Reference Citation Analysis]
17 Brzoska J, von Eick H, Hündgen M. Commentary: Why Haven't We Found an Effective Treatment for COVID-19? Front Immunol 2021;12:714175. [PMID: 34290716 DOI: 10.3389/fimmu.2021.714175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Khazeei Tabari MA, Iranpanah A, Bahramsoltani R, Rahimi R. Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review. Molecules 2021;26:3900. [PMID: 34202374 DOI: 10.3390/molecules26133900] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
19 Kelleni MT. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34088250 DOI: 10.1080/14787210.2021.1939683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O'Farrill-Romanillos PM, Muzquiz Zermeño D, Scheffler Mendoza SC, Venegas Montoya E, García Campos JA, Sánchez-Sánchez LM, Gámez González LB, Ramírez López JM, Bustamante Ogando JC, Vásquez-Echeverri E, Medina Torres EA, Lopez-Herrera G, Blancas Galicia L, Berrón Ruiz L, Staines-Boone AT, Espinosa-Padilla SE, Segura Mendez NH, Lugo Reyes SO. COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. J Clin Immunol 2021. [PMID: 34114122 DOI: 10.1007/s10875-021-01077-5] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
21 Temizoz B, Ishii KJ. Type I and II interferons toward ideal vaccine and immunotherapy. Expert Rev Vaccines 2021;20:527-44. [PMID: 33993812 DOI: 10.1080/14760584.2021.1927724] [Reference Citation Analysis]
22 Costa B, Vale N. A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19. Pharmaceutics 2021;13:815. [PMID: 34070725 DOI: 10.3390/pharmaceutics13060815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vadakedath S, Kandi V, Mohapatra RK, Pinnelli VBK, Yegurla RR, Shahapur PR, Godishala V, Natesan S, Vora KS, Sharun K, Tiwari R, Bilal M, Dhama K. Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review. J Med Virol 2021;93:5295-309. [PMID: 33990972 DOI: 10.1002/jmv.27081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 da Silva RP, Gonçalves JIB, Zanin RF, Schuch FB, de Souza APD. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:657363. [PMID: 34054820 DOI: 10.3389/fimmu.2021.657363] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
25 Kiener M, Roldan N, Machahua C, Sengupta A, Geiser T, Guenat OT, Funke-Chambour M, Hobi N, Kruithof-de Julio M. Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. Front Med (Lausanne) 2021;8:644678. [PMID: 34026781 DOI: 10.3389/fmed.2021.644678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Li X, Peng T. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Front Pharmacol 2021;12:660710. [PMID: 34017257 DOI: 10.3389/fphar.2021.660710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Winstone H, Lista MJ, Reid AC, Bouton C, Pickering S, Galao RP, Kerridge C, Doores KJ, Swanson CM, Neil SJD. The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. J Virol 2021;95:e02422-20. [PMID: 33563656 DOI: 10.1128/JVI.02422-20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 58] [Article Influence: 29.0] [Reference Citation Analysis]
28 Karimi A, Rafiei Tabatabaei S, Shiva F, Hoseinialfatemi SM. COVID-19 or Influenza, or Both? A Comparison and Algorithmic Approach to Management. Jundishapur J Microbiol 2021;13. [DOI: 10.5812/jjm.112121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]